Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Author: ["Martin S Weber","Thomas Prod'homme","Sawsan Youssef","Shannon E Dunn","Cynthia D Rundle","Linda Lee","Juan C Patarroyo","Olaf Stüve","Raymond A Sobel","Lawrence Steinman","Scott S Zamvil"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Treatment with glatiramer acetate (GA, copolymer-1, Copaxone), a drug approved for multiple sclerosis (MS), in a mouse model promoted development of anti-inflammatory type II monocytes, characterized by increased secretion of interleukin (IL)-10 and transforming growth factor (TGF)-β, and decreased production of IL-12 and tumor necrosis factor (TNF). This anti-inflammatory cytokine shift was associated with reduced STAT-1 signaling. Type II monocytes directed differentiation of TH2 cells and CD4+CD25+FoxP3+ regulatory T cells (Treg) independent of antigen specificity. Type II monocyte–induced regulatory T cells specific for a foreign antigen ameliorated experimental autoimmune encephalomyelitis (EAE), indicating that neither GA specificity nor recognition of self-antigen was required for their therapeutic effect. Adoptive transfer of type II monocytes reversed EAE, suppressed TH17 cell development and promoted both TH2 differentiation and expansion of Treg cells in recipient mice. This demonstration of adoptive immunotherapy by type II monocytes identifies a central role for these cells in T cell immune modulation of autoimmunity.
Cite this article
Weber, M., Prod'homme, T., Youssef, S. et al. Type II monocytes modulate T cell–mediated central nervous system autoimmune disease. Nat Med 13, 935–943 (2007). https://doi.org/10.1038/nm1620
